相关实验视频

Updated: Jun 21, 2025

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

鉴定deutetrabenazine延长释放片用于与亨廷顿病相关的晚期动症和胆发病

P Moondra¹, J Jimenez-Shahed²

¹Clinical Movement Disorders Fellow, The Mount Sinai Hospital, New York, NY, USA.

Expert review of neurotherapeutics

|July 10, 2024

概括

延长释放型杜特特拉贝纳 (DTBZ ER) 为晚期动症 (TD) 和亨廷顿病提供每天一次的选择.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
运动障碍运动障碍

背景情况:

晚期动力障碍 (TD) 和亨廷顿病 (HD) 相关的胆病是使人虚弱的高动力运动障碍.
膀单胺转运体2型 (VMAT2) 抑制剂,如德特拉贝纳 (DTBZ),是已知的治疗方法.
现在可以使用新的每日一次 (QD) 延长释放配方 (DTBZ ER).

研究的目的:

审查DTBZ对TD和HD相关胆病的疗效和安全性.
评估支持DTBZ ER (QD) 与DTBZ BID (每天两次) 生物等价性的药理动力学数据.
讨论DTBZ ER的剂量比例,定位和安全性.

主要方法:

对DTBZ在TD和HD相关胆病的关键临床试验的审查.
对药理动力学数据的分析,比较QD和BIDdeutetrabenazine配方.
检查剂量比例性,定位策略和安全概况.

主要成果:

长期数据证实DTBZ在TD和胆病中有效且耐受良好.
DTBZ ER证明了与DTBZ BID相似的生物等价性和生物可用性.
与DTBZ ER没有发现新的安全问题,这表明治疗等价性.

结论:

DTBZ ER为TD和HD相关的慢性病提供了一个潜在的改进剂量方案.
QD剂量可能会提高药物坚持,特别是在认知障碍患者中.
需要进一步的比较数据来指导VMAT2抑制剂的选择和切换.

关键词:

不正常的非自愿运动.亨廷顿氏病的慢性病.这是一种VMAT2抑制剂.德特拉贝纳的使用方法晚期运动障碍症.

更多相关视频

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)

¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)

When proton-coupled carbon-13 spectra are simplified by a broadband proton decoupling technique, structural information about the coupled protons is lost. Distortionless enhancement by polarization transfer (DEPT) is a technique that provides information on the number of hydrogens attached to each carbon in a molecule. While the DEPT experiment utilizes complex pulse sequences, the pulse delay and flip angle are specifically manipulated. The resulting signals have different phases depending on...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...